Retatrutide Beyond Weight: Lipids, BP, and Liver Markers

Most of the conversation about retatrutide metabolic effects starts and ends with weight loss — and understandably so. The Phase 2 trial published in The New England Journal of Medicine in 2023 showed up to 24% weight reduction at 48 weeks, a number that rewrote expectations for what a pharmaceutical could do to the scale. But the weight headline obscures a more interesting story: what's happening to the lipid panel, blood pressure cuff, and liver function tests alongside all that lost weight?

This post digs into the cardiometabolic biomarker data from retatrutide's Phase 2 trial and explains why researchers are watching the glucagon component closely for applications well beyond obesity.

A quick recap: what retatrutide is

Retatrutide is a triple receptor agonist — it targets GLP-1, GIP, and glucagon receptors simultaneously. Each component contributes differently to its metabolic profile:

The glucagon component is what distinguishes retatrutide from semaglutide and tirzepatide most meaningfully. Glucagon receptor agonism increases resting energy expenditure — your body burns more calories at rest — and directly stimulates fat breakdown in the liver and adipose tissue. That combination likely explains both the exceptional weight loss numbers and some of the cardiometabolic changes discussed below.

What happened to lipids

Triglycerides dropped substantially. In the Phase 2 trial, retatrutide-treated participants showed significant reductions in fasting triglycerides across dose groups. The reductions were dose-dependent — larger at higher doses — and were well above what would be expected from caloric restriction alone.

The triglyceride effect makes mechanistic sense: glucagon receptor activation directly promotes hepatic fat oxidation and reduces VLDL secretion from the liver. This is independent of whatever is happening to the diet. Less liver fat being packaged into VLDL means fewer triglycerides entering the bloodstream.

LDL changes were more modest. Retatrutide showed some LDL reduction, but the signal here is less dramatic than the triglyceride effect. This is consistent with how most GLP-1/GIP-based therapies behave — they're not primarily LDL-lowering agents the way statins are. The LDL benefit, where it exists, likely runs mostly through weight loss.

HDL cholesterol improved. Higher HDL is generally associated with cardiovascular risk reduction, and participants in the retatrutide trial showed HDL increases. This pattern is common with significant weight loss and improved insulin sensitivity.

The honest caveat: separating "retatrutide did this" from "losing 20%+ of your body weight did this" is genuinely difficult in a trial where both things happen simultaneously. Lipid improvements of this magnitude are seen with any intervention that produces dramatic weight loss. What's harder to attribute to weight loss alone is the speed and magnitude of triglyceride reduction — the glucagon component may be accelerating changes that would otherwise take longer.

Blood pressure: clinically meaningful reductions

Both systolic and diastolic blood pressure fell significantly in retatrutide-treated participants relative to placebo. The reductions were clinically meaningful — the kind of numbers that, if sustained, translate to reduced cardiovascular event risk.

Again, the weight-vs-drug question arises. Obesity is a major driver of hypertension, and substantial weight loss consistently reduces blood pressure. But the speed of improvement in retatrutide-treated participants — notable even in the early weeks before maximum weight loss was achieved — hints at mechanisms beyond simple weight loss.

One possibility is the kidney. GLP-1 receptors are expressed in the kidney and GLP-1 agonists have natriuretic effects (they promote sodium excretion). Reduced sodium retention means lower blood volume and lower blood pressure. This is likely part of the early blood pressure story. The glucagon component may also directly vasodilate via nitric oxide pathways, though this is less well-characterized in humans.

Liver markers: the MASH connection

ALT and AST (liver enzymes that rise when liver cells are stressed or dying) both improved significantly with retatrutide. Elevated ALT/AST is a hallmark of metabolic dysfunction-associated steatohepatitis, or MASH (previously called NASH) — a serious liver condition affecting a substantial proportion of people with obesity or type 2 diabetes.

The Phase 2 trial wasn't designed as a MASH study — liver biopsy results weren't the primary endpoint — but the enzyme data is a strong enough signal that retatrutide is being actively investigated for MASH. Phase 3 MASH trials are ongoing as of this writing.

Why might retatrutide be particularly well-suited to MASH? A few reasons:

1. Liver fat reduction via glucagon. The glucagon component directly promotes hepatic fat oxidation — it essentially tells the liver to burn stored fat rather than accumulate it. This mechanism is distinct from the indirect liver benefit that comes from eating less.
2. Weight loss magnitude. MASH severity correlates with obesity, and retatrutide's ~24% weight loss is in the range where histological improvement (actual reduction in liver inflammation and scarring) is plausible.
3. Insulin sensitization. Improved insulin sensitivity, driven by GLP-1 and GIP effects, reduces the chronic insulin resistance that drives fat accumulation in the liver.

There are already approved therapies for MASH (resmetirom, approved 2024), so retatrutide will need to demonstrate benefit beyond weight loss alone to carve out a MASH indication. But the mechanistic case is strong.

The HFpEF angle

Heart failure with preserved ejection fraction (HFpEF) is an emerging application for GLP-1-class drugs. HFpEF is particularly common in people with obesity and metabolic syndrome — the overlap is substantial enough that some cardiologists call it "obesity cardiomyopathy." Semaglutide's STEP-HFpEF trial showed meaningful symptom improvement and weight reduction in HFpEF patients.

Retatrutide hasn't yet reported HFpEF-specific trial data, but the broader cardiometabolic profile — blood pressure reduction, improved lipids, weight loss, improved insulin sensitivity — addresses most of the major HFpEF risk drivers. Phase 3 cardiovascular outcomes trials are anticipated.

For context: tirzepatide's cardiometabolic profile shows similar directional improvements, but retatrutide's glucagon component may add energy expenditure and liver fat effects that tirzepatide doesn't have.

What we don't yet know

Phase 2 data tells you the drug does something interesting. It does not tell you:

• Whether the improvements are sustained over years. The Phase 2 trial ran 48 weeks. Cardiovascular outcomes trials take 3–5 years. The cardiometabolic signals are promising, but durability is unproven.
• What happens when you stop. Consistent with other GLP-1-class drugs, weight regain is expected after discontinuation. Whether the lipid, BP, and liver benefits reverse with weight regain is a reasonable assumption but not rigorously documented for retatrutide specifically.
• How it compares head-to-head. No direct comparison of retatrutide vs tirzepatide vs semaglutide on cardiometabolic endpoints has been published. The cross-trial comparisons are suggestive but confounded by different populations and study designs.

Why the glucagon component changes the story

The simplest way to think about retatrutide's cardiometabolic profile is this: semaglutide primarily suppresses appetite; tirzepatide adds a metabolic efficiency boost via GIP; retatrutide adds energy expenditure and direct fat-burning via glucagon.

That third mechanism is why the lipid (especially triglyceride) and liver-fat changes may be more pronounced with retatrutide than with the other agents. The glucagon receptor doesn't do much for appetite, but it is a powerful metabolic dial that directly tells fat tissue and the liver to burn their stores.

For people whose primary concern is weight loss, that may matter less — you care about the number on the scale, and all three agents move it. For people who come in with a lipid panel that looks like a problem, or liver enzymes that their internist keeps flagging, or hypertension that hasn't responded to lifestyle alone, the cardiometabolic breadth of retatrutide's effects is worth understanding.

See our retatrutide overview for the full mechanistic picture, and the weight-loss timeline tool for expectations if you're comparing options.

Related reading

• Why retatrutide loses more weight
• Tirzepatide metabolic effects explained
• GLP-1 side effects: what to watch
• Weight loss timeline by month